Terms ending in 2028
Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,825,118 | Inhibitors of Bruton's Tyrosine Kinase In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 7,838,234 | Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,128,096 | Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 8,748,468 | MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 8,338,416 | Indole Derivatives as Inhibitors of Histone Deacetylase In force · High confidence | Pharmacyclics LLC | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.